Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab beyond progression plus chemotherapy or targeted therapy in second-line extensive-stage small cell lung cancer
ChiCTR2400093930Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Objective response rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400093930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093930.